Pacific Edge slashes team on US 'uncertainty'

Pacific Edge slashes team on US 'uncertainty'
(Image: PEB)
Brent Melville
Pacific Edge has halved its sales team after uncertainty over its future in its core US market, with a pending decision on whether medicare contractor Novitas will cover US testing.  The cancer diagnostic company, dual listed on the New Zealand and Australian stock exchanges, slashed its commercial team from 34 to 17 as it restructured its operations after a 17.78% drop in test volumes for its Cxbladder product in its core US market for the December quarter.The Dunedin firm said it had processed 7,172 tests during the final three months of...

More Markets

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.

These shares are 'priced for awful'
Markets

These shares are 'priced for awful'

Kathmandu, SkyCity and Fletcher shares are under pressure. Some are taking the plunge.